Applicare books record revenues
Applicare books record revenuesDutch PACS software firm Applicare Medical Imaging has posted impressive results for the first eight months of 1999. During this period, the GE Medical Systems subsidiary doubled the total installed base it had at
Applicare books record revenues
Dutch PACS software firm Applicare Medical Imaging has posted impressive results for the first eight months of 1999. During this period, the GE Medical Systems subsidiary doubled the total installed base it had at the end of 1998, and sold 4500 RadWorks software licenses. Almost 600 hospitals and private practices in over 30 countries are now using RadWorks, according to CEO Ruud Kroon.
Applicare has also released version 5.0 of its RadWorks software. The new release includes support for multi-frame images, independent windowing of the magnifying glass, and enhancement of second-generation hanging protocols. Other features include the ability to save studies with a single keystroke, annotation improvements, local worklist composition, enhanced autorouting to multiple destinations, and customization of the user interface. Automatic matching of incoming patient data with DICOM worklist data is provided, as is DICOM lossless JPEG compression, according to the Zeist-based firm.
In other news, GE sales staff are now actively selling RadWorks under the GE logo, Kroon said. In addition, Applicares software-only, NT-based archive (PNN 7/99) entered beta testing in July, with an introduction expected before this years RSNA meeting.
- Search again
- Homepage
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
